Biomedical subjects

A Polubiec

Publications and source records attributed to A Polubiec.

At least 19 recordsLinked to original sources

PubMed2001

[Pseudolymphoma in patients with primary Sjogren's syndrome].

Sjögren's syndrome is an inflammatory autoimmune disease affecting primarily the exocrine glands. In the abscence of other autoimmune diseases it is classified as primary Sjögren's syndrome. Patients with primary syndrome have about 40 times higher relative risk of developing lymphoma then normal population, which offers a possibility to study malignant transformation's mechanisms in these patients. In the study we report a case of a woman with pseudolymphoma. The clinical diagnose used to be based on symptoms of proliferate disease, quetionnable histological evaluation and good response to steroids. Nowadays, applying advanced molecular techniques make it possible to diagnose lymphoma in labial salivary biopsy much earlier. It allows recognizing an incipient lymphoma in a group of patients with primary Sjögren's syndrome. Therefore so-called pseudolymphoma can usually be diagnosed as either benign or malignant lymphoproliferative lesions.

Adult↗

PubMed2000

[Septic-toxic shock due to rhabdomyolysis in a patient treated with fenofibrate].

Lipid disorders have been treated with fibrates for many years. Rhabdomyolysis is one of the side effects of these drugs. We report a case of a septic-toxic shock due to rhabdomyolysis in a 75-year old patient, who had been treated with fenofibrate for 2 years. This case shows necessity of the standard monitoring of aminotransferase, phosphocreatine kinase and creatinine levels during treatment with fibrates.

Aged↗

PubMed1996

[A probe using isotretinoin for treatment of poorly differentiated leukemia].

Isotretinoin (Roaccutane) was used in a patient with low differentiated cell leukemia. Poor general condition, very low blood cell count as well patient's lack of consent made chemotherapy impossible. The effect of isotretinoin treatment was full hematological and clinical remission. The general patient's condition did not require additional medication.

Aged↗

PubMed1992

Evaluation of the antiemetic effect of domperidon in patients treated with cytostatic drugs.

Forty patients with various neoplastic syndromes received domperidon as a drug reducing nausea and vomiting. The drug prevents in the daily dose of 30 mg completely the occurrence of nausea and vomiting in 30% of the patients and in 58% considerably reduces their intensity. The dose of 60 mg abolishes nausea and vomiting in 60% of the patients and alleviates in 35%. The drug had been administered through the whole period of chemotherapy without any side effects which may be attributed to its antagonist action to dopamine.

Adolescent↗

PubMed1991

[Results of treatment of breast cancer with tamoxifen].

There were 62 cases of mammary carcinoma treated with the antioestrogen tamoxifen. The age of the patients ranged from 35 to 75 years. Tamoxifen was administered in a daily dosage of 30 mg (3 x 1 tablet). Treatment was carried out as monotherapy or adjuvant therapy. Treatment was carried out for 6 months with a follow-up period of further 6 months. In the group of patients with mammary carcinoma, 23 were premenopausal without metastases after radical mastectomy and sterilisation. The remaining 39 in this group were in the menopause with metastases which were in some cases untreated and in some cases treated by mastectomy, radiation and chemotherapy (CMF-scheme). All Patients were PD in relation to further radiation and/or chemotherapy. Karnofsky-index was 60 minimum. After 4 weeks' treatment with tamoxifen both an improvement in general wellbeing and a regression of the focus of the tumour was achieved. A significant improvement in wellbeing and tumour status could be established for a total of 48 cases of mammary carcinoma. Treatment was well tolerated. Only 1 case of side effects in the form of vomiting occurred.

Adult↗

PubMed1990

Results of the treatment of cardiac arrhythmias with Palpitin.

1) Palpitin has distinguishable antiarrhythmic effect in different type of cardiac arrhythmias of both supraventricular and ventricular origin, and of various ethiopathogeneses. 2) Antiarrhythmic effect is observed in most patients, already 24 hours after initiation of treatment. 3) Untoward effects, although occurring relatively frequently, usually do not cause such severe alterations which lead to a discontinuance of therapy. 4) Palpitin may be used in long-term treatment of outpatients.

Adult↗

PubMed1988

Bacterial infections of the lower urinary tract treated with ciprofloxacin or cefalexin--a comparative study.

30/30 patients with lower UTI were enrolled in a randomized study to compare ciprofloxacin (250 mg/b.i.d.) and cefalexin (1 g/t.i.d.). In addition, 59 patients with cefalexin-resistant bacterial strains were treated in an open study arm. Ciprofloxacin showed convincingly better clinical and bacteriological efficacy than cefalexin. Both antibiotics were well tolerated. Ciprofloxacin has proved to be superior to cefalexin in the treatment of lower UTI.

Adult↗

PubMed1987